The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Let’s discuss how Tardive Dyskinesia (TD) affects your life and what you can do to overcome these difficulties.

Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a compa ...

While they can work well, they carry a higher risk of side effects, including a serious long-term side effect, tardive dyskinesia (TD), an involuntary movement disorder in which people may experience ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average ...

Assemblyman Jeff Gonzalez (R-Indio) announced Monday the introduction of AB 641, which would create a public awareness ...

After suffering from a long battle with Tardive Dyskinesia and Parkinsons Disease Glenn R. Buddy Clark, age 69, passed away at the South Mountain Restoration Center on Sunday, February 16 ...

Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market where stock prices, most commonly of small-cap stocks, rise in the month of ...